Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.

{"title":"Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.","authors":"Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar, John C Morris, Mabel Ryder, Alan L Ho, Mark Agulnik, Lai Wei, Demond Handley, Catherine Moses, Rajani Jacob, John Wright, Howard Streicher, William Carson, Manisha H Shah","doi":"10.1210/clinem/dgaf221","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf221","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}